AbCellera Phase 2 trial shows ABCL635 cuts hot flash frequency by 83%

August 10, 2026 7:00 AM

AbCellera Biologics (Nasdaq: ABCL) announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found